Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy
Recruitment status was Recruiting
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, also known as statins, played an important role in lipid-lowering therapy and reduction of cardiovascular risks. However, it has been observed that the response to statin therapy varies from patient to patient, and gene polymorphism could have contributed to the variation.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy|
blood samples are obtained for genomic DNA extraction.
|Study Start Date:||March 2007|
|Estimated Study Completion Date:||February 2010|
Hyperlipidemic patients are retrospectively screened from 2006/1/1 to 2006/12/31. The patient is included if he or she had been receiving atorvastatin or rosuvastatin for at least 3 months and did not receive other lipid-lowering medications 4 weeks before starting atorvastatin or rosuvastatin. Genomic DNA was collected from the blood sample of each patient using genomic DNA purification kit. The single nucleotide polymorphisms (SNPs) were determined afterward.
The correlation between response of statin therapy, defined as changes in lipid profiles including triglyceride, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol, and SNPs examined.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00509574
|Contact: Tzung-Dau Wang, MD, PhD||886-2-2312-3456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Principal Investigator:||Tzung-Dau Wang, MD, PhD||Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital|